TURALIO ® Risk Evaluation and Mitigation Strategy Program (tREMS): 3-year retrospective hepatic safety assessment

Author:

Dharmani Charles1ORCID,Fofah Oluwatosin1ORCID,Fallon Maura2ORCID,Rajper Abdul Waheed3ORCID,Wooddell Margaret4ORCID,Salas Maribel1ORCID

Affiliation:

1. Global Epidemiology, Daiichi Sankyo, Inc., Basking Ridge, NJ 07920, USA

2. Clinical Safety & Pharmacovigilance, Daiichi Sankyo UK Ltd., Uxbridge, UB8 1DH, UK

3. Clinical Safety & Pharmacovigilance, Daiichi Sankyo, Inc., Basking Ridge, NJ 07920, USA

4. Global Oncology Medical Affairs, Daiichi Sankyo, Inc., Basking Ridge, NJ 07920, USA

Funder

Daiichi Sankyo, Inc.

Publisher

Informa UK Limited

Reference19 articles.

1. Daiichi Sankyo. TURALIO® (pexidartinib) capsules, for oral use [package insert]. Basking Ridge, NJ: Daiichi Sankyo, Inc.; 2023.

2. Pexidartinib: first approved systemic therapy for patients with tenosynovial giant cell tumor

3. Pexidartinib (TURALIO™): The First FDA-Indicated Systemic Treatment for Tenosynovial Giant Cell Tumor

4.

Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development

5. de Saint Aubain Somerhausen N, van de Rijn M. Tenosynovial giant cell tumour, diffuse type. In: World Health Organization classification of tumours of soft tissue and bone. 4th ed., Lyon, France: IARC Press; 2013. p. 102–103.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3